Add Vivus (VVUS +4.1%) to the list of companies showing a gain on speculation that demand for...


Add Vivus (VVUS +4.1%) to the list of companies showing a gain on speculation that demand for obesity drugs will take off following Orexigen's (OREX +52%) restart on development of Contrave. The momentum buying looks to be led by loose talk the FDA will ease obesity drug standards, which doesn't quite fall in line with analysts and the agency itself (I, II).

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs